10-K: Labcorp Reports Strong 2025 Growth, Strategic Expansion

Labcorp Holdings Inc. reported a 7.2% revenue increase to $13.95 billion in 2025, driven by organic growth and strategic acquisitions, while navigating healthcare cost pressures and investing in specialty testing and AI.

Summary

• Total revenues for 2025 were $13,951.7 million, a 7.2% increase from $13,008.9 million in 2024, driven by 4.4% organic growth and 2.5% from acquisitions.
• The Diagnostics Laboratories (Dx) segment revenue increased by 7.2% to $10,876.5 million, with organic volume up 2.2% and price/mix up 3.5%.
• The Biopharma Laboratory Services (BLS) segment revenue increased by 6.0% to $3,098.2 million, primarily due to 4.0% organic growth and 2.0% favorable foreign currency translation.
• Operating income increased by 27.4% to $1,384.7 million in 2025 from $1,086.7 million in 2024.
• Net earnings attributable to Labcorp Holdings Inc. were $876.5 million in 2025, up from $746.0 million in 2024, resulting in diluted EPS from continuing operations of $10.46.
• The company invested $582.0 million in strategic business acquisitions during 2025, including a 15% minority stake in SYNLAB for approximately $151.6 million.
• Capital was returned to shareholders through $450.0 million in share repurchases (1.8 million shares at an average price of $254.17) and $240.7 million in dividends.
• Restructuring and other charges significantly increased to $127.2 million in 2025, up 176.5% from $46.0 million in 2024, largely due to $105.5 million associated with the restructuring of Early Development (ED).
• Cash and cash equivalents decreased from $1,518.7 million at the end of 2024 to $532.3 million at the end of 2025.
• The U.S. government enacted the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, which includes provisions that could lead to revised regulatory requirements and reduced federal funding for healthcare, though the company believes any material impact on future operations is unlikely.
• The Transition Services Agreement (TSA) with Fortrea expired on June 30, 2025, leading to a $76.2 million decrease in fees charged to Fortrea compared to the prior year, impacting 'Other, net' expense.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with significant revenue and operating income growth, strategic expansions, and effective capital deployment, despite some increased restructuring costs and ongoing legal challenges.

Positives

• Achieved strong total revenue growth of 7.2% to $13,951.7 million in 2025, driven by 4.4% organic growth and 2.5% from strategic acquisitions.
• Operating income increased significantly by 27.4% to $1,384.7 million, demonstrating improved operational leverage.
• Both the Dx and BLS segments showed improved operating margins, with Dx up 50 basis points to 16.4% and BLS up 40 basis points to 16.1%.
• Successfully signed or completed 13 collaboration transactions with health systems and local/regional laboratories in 2025, expanding market presence.
• Expanded specialty testing offerings with new tests for Alzheimer's disease, molecular residual disease, and oncology, aligning with high-growth clinical areas.
• Increased capacity in cell and gene therapy laboratory in Madison, Wisconsin, supporting acceleration in this critical R&D area.
• Expanded consumer-centric capabilities by launching nationwide self-collection options for human papillomavirus and sexually transmitted infection testing.
• Supported approximately 85% of new drugs and therapeutic products approved by the FDA in 2025, highlighting a strong position in drug development.
• Returned substantial capital to shareholders, including $450.0 million in share repurchases and $240.7 million in dividends.
• Maintained effective internal control over financial reporting as of December 31, 2025.
• The OBBBA will enable the company to accelerate the realization of $194.7 million of deferred tax assets relating to R&D costs over the next two years.

Negatives

• Restructuring and other charges increased significantly by 176.5% to $127.2 million in 2025, primarily due to $105.5 million associated with the restructuring of Early Development (ED).
• Equity method loss, net increased substantially to $(13.3) million in 2025, primarily due to the loss recognized from the SYNLAB investment.
• The 'Other, net' category experienced a significant decrease to $(55.0) million in 2025, largely due to a $76.2 million decrease in fees from the Fortrea TSA expiration and increased net investment losses of $42.6 million.
• Cash and cash equivalents decreased by $986.4 million, from $1,518.7 million in 2024 to $532.3 million in 2025.
• Interest expense increased by 7.6% to $224.1 million due to higher weighted-average interest rates.
• Ongoing legal proceedings, including a patent infringement lawsuit with Ravgen Inc., resulted in a $272.0 million jury verdict, $100.0 million in enhanced damages, and $2.6 million in post-verdict supplemental damages, plus an ongoing royalty of $100 per test, which the company is appealing.
• A class action lawsuit alleging inaccessible touchscreen kiosks for visually impaired patients at patient service centers had class certification affirmed by the Ninth Circuit.

Risks

• Changes in government and third-party payer regulations, reimbursement, or coverage policies, including the impact of PAMA, could adversely affect revenues and profitability.
• Significant monetary damages and penalties, and/or exclusion from government programs, arising from enforcement of anti-fraud and abuse laws.
• Significant fines, penalties, costs, and damage to reputation from failure to comply with privacy and security laws and regulations (e.g., HIPAA, CCPA, GDPR).
• Increased competition, including price competition, competitive bidding, and changes or reductions to fee schedules.
• Failure to retain or attract business from MCOs or new customers, or a reduction in tests ordered by existing customers.
• Consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, and supply chain access.
• Inability to attract, retain, and develop experienced and qualified personnel, including in key roles, and increased personnel costs.
• Failure to develop or acquire licenses for new or improved technologies, or customers using new technologies (e.g., point-of-care testing, AI) to replace company offerings.
• Disruption in services, supplies, or transportation provided by third parties, or discontinuation/recall of existing products.
• Failure to identify, successfully close, and effectively integrate acquisitions, or inability to achieve expected benefits and synergies from acquired businesses.
• Unfavorable labor environments, union strikes, work stoppages, or failure to comply with labor laws.
• Damage or disruption to facilities or operations from natural disasters, geopolitical events, public health crises, or criminal activity.
• Failure to establish, update, or perform to appropriate quality standards.
• Financial risk for contracts that may be underpriced, subject to cost overruns, delayed, or terminated.
• Significant increase in days sales outstanding, increasing bad debt or decreasing cash flow.
• Dependence of BLS revenues on R&D spending by pharmaceutical, biotechnology, and medical device industries.
• Foreign currency exchange fluctuations, especially for BLS's non-U.S. operations.
• Risks from financial instruments used to limit exposure to interest rate and currency exchange fluctuations.
• High level of indebtedness ($5.2 billion outstanding senior notes at December 31, 2025) and debt service requirements could adversely affect liquidity.
• Quarterly results of operations may vary significantly due to global economy, currency rates, project timing, external events, and acquisition costs.
• Default or failure of financial institutions where the company maintains cash and cash equivalents.
• Restrictions on capital raising or strategic transactions due to the tax-free qualification of the Fortrea Spin-off.
• Cybersecurity incidents and unauthorized access to data, including ransomware, data breaches, and phishing, exacerbated by AI use by threat actors and remote work.
• Risks associated with the use of AI and machine learning tools, including data leaks, flawed outputs, biased decisions, and new security threats.
• Violations of anti-fraud and abuse laws (e.g., Anti-Kickback Statute, Stark Law, False Claims Act).
• Loss or suspension of licenses or imposition of fines/penalties under CLIA, Medicare, Medicaid, or other national/state/local agencies.
• Noncompliance with national security, privacy, and data security laws (e.g., HIPAA, CCPA, GDPR, DOJ's Data Security Program).
• Additional risks and expenses from international operations, including anti-corruption laws (FCPA, U.K. Bribery Act), trade sanctions, and unclear legal frameworks.
• Failure to comply with regulations of pharmaceutical and medical device regulators (e.g., FDA, MHRA, EMA) for preclinical and central laboratory operations.
• Increased regulations and restrictions on the import/supply of research animals, and actions of animal rights activists.
• Diseases in animal populations used for preclinical services.
• U.S. FDA regulation of Laboratory Developed Tests (LDTs) and regulation by other countries of diagnostic offerings could increase regulatory burdens.
• Failure to comply with environmental, health, and safety laws and regulations.
• Negative impact on business and reputation from views on corporate responsibility and governance.
• Adverse results in material litigation matters, including intellectual property disputes (Ravgen lawsuit), class actions (AMCA Incident, visually impaired patient kiosks), and government inquiries.
• Liability risks from contract services in the drug development industry, including errors/omissions, animal-related risks, and indemnification obligations.
• Changes in tax laws and regulations or their interpretation.

Future Outlook

The company expects capital expenditures to increase to approximately 4.0% of revenues in 2026 to support core business growth, facility expansions, LaunchPad initiatives, and acquisition integration. It anticipates remaining in compliance with all debt covenants for the next 12 months. While the One Big Beautiful Bill Act (OBBBA) could lead to reduced federal funding and diagnostic testing utilization, the company currently believes any such reduction would not likely have a material impact on its results of operations in future periods. PAMA rate decreases are frozen for 2026 but will resume in 2027, capped at 15% per year through 2029, with a data collection period for private payer rates from January 1, 2025, to June 30, 2025, and reporting to CMS from May 1, 2026, to July 31, 2026, to set CLFS prices for 2027-2029. The company also expects to contribute approximately $8.4 million to its defined benefit pension plans in 2026.

Management Comments

• "Through leadership in science, technology and innovation, the Company provides vital information and services to help its customers make clear and confident decisions to improve health and improve lives."
• "The Company is expanding its role in the rapidly evolving healthcare market by strengthening its positions across its portfolio of capabilities, growing strategic opportunities that drive new business, and differentiating its unique offerings."
• "The Company believes it is an attractive partner for hospitals, health systems, and local and regional laboratories due to its: innovative offerings in high-growth specialty areas; industry-leading test portfolio and national presence; differentiated data and analytics capabilities; and proven track record of integrating laboratory services."
• "The Company believes its scale, scientific expertise, and broad customer relationships position it to expand its consumer-centric offerings over time to address evolving patient needs."
• "The Company believes these capabilities support its ability to serve as an end-to-end partner to biopharma customers and to drive further targeted growth internationally over time."
• "The Company believes that its comprehensive and expanding test menu, focus on high-growth clinical areas, leading position in companion diagnostics, broad geographic footprint, and operating efficiency position it to compete effectively in this evolving environment."
• "The Company believes it has a strong track record of deploying capital to investments that enhance the Company’s business and return capital to shareholders."
• "The Company believes in the power of science to change lives. The Company’s culture centers around its mission to improve health and improve lives."
• "The Company believes that its investments in compensation and employee well-being are crucial to maintaining comprehensive positioning and a productive, engaged workforce."
• "The Company is committed to developing and commercializing technology-enabled solutions it believes will support its operations and provide better care."
• "The Company approaches the use of AI with an emphasis on responsible deployment, supported by governance structures, ethical guidelines, and cross-functional oversight designed to promote transparency, data protection, and appropriate use of AI technologies."
• "Based on current and projected levels of cash flows from operations, coupled with availability under its revolving credit facility, the Company believes it has sufficient liquidity to meet both its anticipated short-term and long-term cash needs for the next 12 months and the reasonably foreseeable future."

Industry Context

StockSavvy.ai notes that Labcorp's strong revenue growth and improved operating margins in both Diagnostics and Biopharma Laboratory Services segments demonstrate resilience and effective strategy execution in a dynamic healthcare market. The focus on high-growth specialty areas like oncology, women's health, autoimmune disease, and neurology, along with expansion in cell and gene therapy, aligns with broader industry trends towards precision medicine and advanced diagnostics. The company's continued investment in AI and consumer-centric capabilities positions it well against competitors adapting to digital transformation and patient empowerment. The increase in restructuring charges, particularly in Early Development, suggests ongoing optimization efforts to maintain competitiveness in the evolving drug development landscape, where R&D spending remains high but efficiency pressures are constant. The acquisition of a minority stake in SYNLAB highlights a strategic move to expand international reach, a common growth vector for global laboratory service providers.

Comparison to Industry Standards

• Labcorp's 7.2% revenue growth in 2025 compares favorably to the broader U.S. clinical laboratory testing industry, which generated over $80 billion in revenues in 2025, indicating strong market penetration and strategic effectiveness.
• The company's support for approximately 85% of new drugs and therapeutic products approved by the FDA in 2025, including 81% of oncology-related approvals and 86% of biotechnology company approvals, positions it as a leading partner in drug development, comparable to top-tier Contract Research Organizations (CROs) like IQVIA or PPD, which also boast extensive contributions to drug approvals.
• The acquisition of a 15% minority stake in SYNLAB, a European leader, reflects a strategy similar to global expansion efforts by peers like Quest Diagnostics, which also seeks to broaden its international footprint and specialty testing capabilities.
• The increase in Dx operating margin by 50 basis points and BLS operating margin by 40 basis points suggests effective cost management and pricing power, potentially outperforming some smaller, less integrated competitors facing more acute reimbursement pressures.

Corporate Governance

Legal Proceedings

• **Texas Medicaid Billing Lawsuit**: A qui tam petition alleges the company submitted higher-than-permitted claims and offered remuneration to healthcare providers. The District Court's partial summary judgment for the company was reversed by the Texas Court of Appeals. The Texas Supreme Court granted the company's Petition for Review on January 16, 2026. The company will vigorously defend the lawsuit.
• **AMCA Incident Litigation**: Consolidated class action lawsuits allege the company did not adequately protect patient data and failed to timely notify patients of a 2019 security incident at an external collection agency (AMCA). A term sheet for settlement was reached on November 25, 2025, subject to court approval.
• **Shareholder Derivative Lawsuit (Raymond Eugenio)**: Filed April 23, 2020, this lawsuit asserts derivative claims against the company's board of directors and certain executive officers for alleged failure to ensure proper cybersecurity safeguards and implement a sufficient response to data security incidents, including the AMCA Incident. The lawsuit is currently stayed pending resolution of the multi-district litigation related to the AMCA Incident.
• **Visually Impaired Patient Kiosk Lawsuit (Luke Davis and Julian Vargas)**: A class action lawsuit filed January 31, 2020, alleges the company's touchscreen kiosks at Patient Service Centers are inaccessible to visually impaired patients, violating the Americans with Disabilities Act. Class certification was granted and affirmed by the Ninth Circuit. The U.S. Supreme Court granted, then dismissed, the company's Petition for Writ of Certiorari. The company will vigorously defend the lawsuit.
• **Ravgen Patent Infringement Lawsuit**: Filed October 16, 2020, alleging willful infringement of two patents. A jury awarded $272.0 million in damages in September 2022. The court awarded an additional $100.0 million in enhanced damages in May 2023, and $2.6 million in post-verdict supplemental damages, plus an ongoing royalty of $100 per test, in January 2025. The company filed an appeal on March 18, 2025, and strongly disagrees with the verdict.
• **Meta Pixel Class Action Lawsuit (Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds)**: Filed June 7, 2023, alleging the company's website used Meta Pixel to send patient information to Meta. The parties reached a settlement in principle on January 16, 2026, which is subject to the execution of a settlement agreement and court approval.
• **DOJ Subpoena (Urine Drug Testing)**: A Subpoena Duces Tecum was issued by the DOJ on June 27, 2022, requiring the production of documents related to urine drug testing. The company is cooperating with the DOJ.

Related Party Transactions

• The Transition Services Agreement (TSA) between Fortrea Holdings Inc. and Laboratory Corporation of America Holdings (LCAH) expired on June 30, 2025. This resulted in a $76.2 million decrease in fees charged to Fortrea in 2025 compared to 2024, which impacted the 'Other, net' expense.

Stakeholder Impact

• **Shareholders**: Experienced positive impact from increased net earnings and diluted EPS, along with significant capital returns through share repurchases ($450.0 million) and dividends ($240.7 million). However, ongoing legal liabilities and regulatory uncertainties pose potential risks.
• **Employees**: Benefited from talent initiatives, an increased minimum hourly wage to $17.75/hour for U.S.-based non-union employees, $103 million in annual merit increases, and comprehensive well-being programs. Restructuring activities, particularly in Early Development, may have impacted some personnel.
• **Customers (Physicians, Hospitals, Pharmaceutical/Biotechnology Companies)**: Gained from enhanced service offerings through strategic acquisitions and expansion in high-growth specialty testing areas. Improved digital platforms and AI-enabled tools aim to support clinical decision-making and drug development. Potential impacts from evolving reimbursement policies and increased competition remain.
• **Patients**: Received expanded access to advanced diagnostics, consumer-centric offerings like self-collection options, and an improved patient journey through digital capabilities. However, past data security incidents (AMCA) and ongoing accessibility lawsuits (kiosk lawsuit) highlight areas of concern.
• **Creditors**: The company maintains investment-grade credit ratings and was in compliance with all covenants under its credit facilities and indentures at December 31, 2025, indicating stable creditworthiness despite a high level of indebtedness ($5.2 billion in senior notes).

Next Steps

• Continue evaluating the impact of the One Big Beautiful Bill Act (OBBBA) on business and operations as its provisions become effective through 2028.
• Increase capital expenditures to approximately 4.0% of revenues in 2026 to support core business growth, facility expansions/upgrades, LaunchPad initiatives, and acquisition integration.
• Make approximately $8.4 million in required contributions to defined benefit pension plans during 2026.
• The acquisition of select clinical laboratory assets from Empire City Laboratories, Inc. closed in the first quarter of 2026.
• The acquisition of select assets of the outreach business from Parkview Health System, Inc. is anticipated to close in 2026, subject to customary closing conditions and applicable regulatory approvals.
• Payment of a cash dividend of $0.72 per share of Common Stock on March 12, 2026, to stockholders of record as of February 27, 2026.
• Vigorously defend the lawsuit through the appeal process in the Ravgen patent infringement case.
• Finalize the formal settlement agreement and seek court approval for the Meta Pixel class action lawsuit.
• Cooperate with the DOJ's Subpoena Duces Tecum related to urine drug testing.

Key Dates

Recommendation

Labcorp demonstrates solid operational performance with strong revenue and operating income growth, driven by strategic acquisitions and organic expansion in key specialty areas. The company's commitment to innovation, including AI and consumer-centric solutions, positions it well for future growth. However, significant legal liabilities, particularly the ongoing Ravgen patent infringement appeal with substantial damages, and the potential for increased regulatory scrutiny and reimbursement pressures, introduce considerable uncertainty. While the core business is robust, these unresolved legal and regulatory challenges warrant a cautious 'hold' recommendation until their financial impact and resolution become clearer.

Keywords

Laboratory services, Diagnostics, Biopharma, Clinical trials, Healthcare, Medical testing, R&D, SEC filing, 10-K, Labcorp, LH, Corporate governance, Financial results, Risk management, Acquisitions, Specialty testing, AI, Cybersecurity, Reimbursement, PAMA, HIPAA, GDPR